British pharmaceutical giant GlaxoSmithKline revealed that European authorities have approved its new inhaled drug Relvar for treating patients with asthma and chronic obstructive pulmonary disease (COPD).
The drug is supposed to be inhaled through a palm-sized device called Ellipta and is made up of a corticosteroid, to reduce inflammation, and a novel long-acting beta-agonist that will help to open the airways.
Asthma
It''s a lung condition characterized by inflammation of the bronchi and constriction of the airways that result in coughing, wheezing or breathlessness. Allergy and other airway irritants can trigger it
Advertisement
Relvar has been developed in collaboration with Theravance and has already been approved in the United States, where it has been launched under the brand name Breo, though only for treating COPD patients. The approval by European Commission will see Theravance pay $15 million to GSK while a similar payment will be made once the product is launched across the EU.
Source: Medindia
Respiratory Diseases
Respiratory diseases affect any part of the respiratory system. Some of the lung diseases like chronic obstructive pulmonary disease can lead to respiratory failure.
Advertisement
Advertisement
|
Advertisement
Latest Drug News
The drug baricitinib can safely and effectively maintain the body's natural insulin production while inhibiting the advancement of Type 1 diabetes.
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.